The person, family members and caregivers affected by genetic disease are the biggest drivers in every decision our Company makes. From hiring new employees to determining new research initiatives to beginning development programs, we consider the patient community first and foremost.

We continuously seek opportunities to learn from the patients we serve and to provide opportunities to share information about our programs. While we are still in the early stages of clinical development, we are moving forward as quickly as possible, knowing that there are people waiting on new advances. You can learn more about our therapeutic areas or email your questions to patientadvocacy@homologymedicines.com.

You can also learn more about gene therapy and gene editing by watching our recent webinar about new treatment approaches for genetic diseases including phenylketonuria (PKU), which was produced in partnership with the National PKU Alliance.